Browse > Article

Case report : The Bisphosphonate-associated Osteonecrosis of the Jaw(BONJ)  

Kim, Kyun-Yo (Dept. of Oral Medicine, School of Dentistry, Kyungpook National University)
Ko, Yu-Jung (Dept. of Oral Medicine, School of Dentistry, Kyungpook National University)
Hur, Yun-Kyung (Dept. of Oral Medicine, School of Dentistry, Kyungpook National University)
Choi, Jae-Kap (Dept. of Oral Medicine, School of Dentistry, Kyungpook National University)
Publication Information
Journal of Oral Medicine and Pain / v.34, no.3, 2009 , pp. 295-301 More about this Journal
Abstract
Recently, bisphosphonate-associated osteonecrosis of the jaw(BONJ) is added to the list of diseases of the oromaxillofacial region. BONJ is defined as exposed bone in the jaw that does not heal within 8 weeks after identification, in a patient who has been received to bisphosphonates and has not taken radiation therapy to the craniofacial region. Bisphosphonates binded to bone mineral are concentrated in highly active remodeling site, reside in the skeleton for a long time, and do a role as powerful inhibitors of bone resorption. As the patients receiving bisphosphonates therapy grow in number, the patients of BONJ would go on increasing in Korea. We would like to present two patients who were suspected to BONJ, describe the outline of BONJ, and mention importance of our understanding about BONJ. BONJ is rare disease, but once it develops, its prognosis is very poor. Our adequate understanding of BONJ is necessary to prevent it and cope with it properly.
Keywords
Bisphosphonate; Osteomyelitis; Osteonecrosis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 American dental association. Dental Management of Patients Receiving Oral Bisphosphonate Therapy-Expert Panel Recommendations: Report of the council on scientific affirs. 2008
2 Marx RE. Pamidronate(AREDIA) and zoledronate (ZOMETA) induced avascular necrosis of the jaws:a growing epidemic. J Oral Maxillofac Surg 2003;61: 1115-1118   DOI   ScienceOn
3 Twiss IM. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharm Sci 1994;83:699–703   DOI   PUBMED   ScienceOn
4 Nathaniel S. Painful ulcerations in patients with bisphosphonate-associated osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:e1-e4   DOI
5 Kasper et al. Harrison's princeples of internal medicine. 16th ed.-vol.2, 2006. McGrow-Hill, pp.2397-2407
6 Khamaisi M. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-1175   DOI   ScienceOn
7 Fournier P. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002;62:6538   PUBMED
8 Ohe JY. Features of histophatologic and radiographic findings in bisphosphonate-related osteonecrosis of jaw-clinical review. J Kor Oral Maxillofac Surg 2008;34:550-554
9 Phal PM. Imaging Findings of Bisphosphonate-Associated Osteonecrosis of the Jaws. Am J Neuroradiol 2007;28:1139-1145   DOI   ScienceOn
10 Papapoulos SE. Bisphosphonates: how do they work? Best practice and research clinical endocrinology and metabolism 2008;22(5):831-847   DOI   PUBMED   ScienceOn
11 American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws, J Oral Maxillofac Surg 2007;65:369-376   DOI   ScienceOn
12 Treister N. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Diseases 2009;15:88-92   DOI   ScienceOn
13 Kwon YD. Is it an emerging risk factor in oral surgery? J Kor Maxillofac Plastic Recon Surg 2007;29:456-462
14 Marx RE. Bisphosphonate-Induced Exposed Bone(Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment. J Oral Maxillofac Surg 2005;63:1567-1575   DOI   ScienceOn
15 Rogers MJ. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Design 2003;9:2643–2658   DOI   PUBMED   ScienceOn
16 Ott SM. Editorial: Long-Term Safety of Bisphosphonates. J Clin Endocrinol Metab March 2005; 90(3):1897–1899   DOI   PUBMED   ScienceOn
17 Bedogni A. Bisphosphonate-associated jawbone osteonecrosis : correalation between imaging techniques and histopathology. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008;105:358-64   DOI   ScienceOn
18 Eugene P. Seconday osteoporosis : Underlying disease and the risk for glucocorticoid-induced osteoporosis. Clinical Therapeutics 2004;26(1):1-14   DOI   PUBMED   ScienceOn
19 Landesberg R. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008;66:839–847   DOI   PUBMED   ScienceOn
20 Khosla S. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research October 2007;22:1479-1491   DOI   ScienceOn
21 Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: Diagnosis, staging, prevention and management. Annu Rev Med 2009;60:85-96   DOI   ScienceOn
22 Demerjian N. Severe oral ulcerations induced by alendronate. Clin Rheumatol 1999;18:349-350   DOI   ScienceOn
23 Ruggiero SL. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-441   DOI   ScienceOn